Literature DB >> 7517823

The pharmacology of tramadol.

P Dayer1, L Collart, J Desmeules.   

Abstract

(+/-)-Tramadol is a central analgesic with low affinity for opioid receptors. The rate of production of its M1 metabolite (O-demethyl tramadol) is influenced by debrisoquine-type polymorphism, and this metabolite shows a higher affinity for opioid receptors than the parent drug. Experimental and clinical data suggest that tramadol may also exert its analgesic effect through direct modulation of central monaminergic pathways. Indeed, after a single oral dose, the role of the mu-receptor agonist component of the antinociceptive effect of tramadol appears to be minor, with most of the analgesic effect being attributable to nonopioid properties of the parent compound. Approximately 2-fold accumulation of the parent compound and the M1 metabolite may be expected during multiple dose treatment. The duration of analgesic effect after a single oral dose of tramadol 100 mg is about 6 hours. Clinical experience has confirmed that tramadol is an effective and relatively safe analgesic that may be of value in several pain conditions not requiring treatment with strong opioids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517823     DOI: 10.2165/00003495-199400471-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  19 in total

1.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers.

Authors:  D Coquoz; H C Porchet; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

3.  Effect of the opioid analgesic tramadol on inactivation of norepinephrine and serotonin.

Authors:  H H Hennies; E Friderichs; K Wilsmann; L Floh e
Journal:  Biochem Pharmacol       Date:  1982-04-15       Impact factor: 5.858

4.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

Authors:  P Dayer; J Desmeules; T Leemann; R Striberni
Journal:  Biochem Biophys Res Commun       Date:  1988-04-15       Impact factor: 3.575

5.  Central analgesic effect of acetaminophen but not of aspirin.

Authors:  P Piletta; H C Porchet; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

6.  [Biotransformation of tramadol in man and animal (author's transl)].

Authors:  W Lintz; S Erlaçin; E Frankus; H Uragg
Journal:  Arzneimittelforschung       Date:  1981

Review 7.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

8.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  Bioavailability of enteral tramadol formulations. 1st communication: capsules.

Authors:  W Lintz; H Barth; G Osterloh; E Schmidt-Böthelt
Journal:  Arzneimittelforschung       Date:  1986-08

Review 10.  New clinical experience with tramadol.

Authors:  A Sunshine
Journal:  Drugs       Date:  1994       Impact factor: 9.546

View more
  25 in total

1.  Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed.

Authors:  Karel Allegaert; Dick Tibboel; Gunnar Naulaers; Denise Tison; Annick De Jonge; Monique Van Dijk; Christine Vanhole; Hugo Devlieger
Journal:  Eur J Clin Pharmacol       Date:  2003-04-04       Impact factor: 2.953

2.  An evaluation of analgesic efficacy and clinical acceptability of intravenous tramadol as an adjunct to propofol sedation for third molar surgery.

Authors:  E A Shipton; J A Roelofse; R J Blignaut
Journal:  Anesth Prog       Date:  2003

3.  Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy.

Authors:  H Potschka; E Friderichs; W Löscher
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Tramadol analgesia. Synergy in research and therapy.

Authors:  J M Besson; M D Vickers
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 5.  Tramadol for postoperative pain treatment in children.

Authors:  Alexander Schnabel; Sylvia U Reichl; Christine Meyer-Frießem; Peter K Zahn; Esther Pogatzki-Zahn
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

6.  [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].

Authors:  A V Bono; S Cuffari
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Tramadol induced seizure: A 3-year study.

Authors:  Reza Boostani; Siavash Derakhshan
Journal:  Caspian J Intern Med       Date:  2012

8.  Pharmacokinetics of intravenous tramadol in dogs.

Authors:  Chantal J McMillan; Alex Livingston; Chris R Clark; Patricia M Dowling; Susan M Taylor; Tanya Duke; Rolf Terlinden
Journal:  Can J Vet Res       Date:  2008-07       Impact factor: 1.310

9.  Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice.

Authors:  Meredith A Fox; Catherine L Jensen; Dennis L Murphy
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-11       Impact factor: 5.176

10.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.